2,3-二甲基丁-2-烯二酸 | 21788-49-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2,3-二甲基丁-2-烯二酸
• 中文别名: 二甲基富马酸
• 英文名称: (E)-2,3-dimethyl-2-butenedioic acid
• 英文别名: (E)-2,3-dimethylbut-2-enedioic acid；2,3-Dimethylfumaric acid；dimethylfumaric acid；Dimethylfumarsaeure；Dimethyl-fumarsaeure
• CAS: 21788-49-8
• 化学式: C₆H₈O₄
• 分子量: 144.127
• InChiKey: CGBYBGVMDAPUIH-ONEGZZNKSA-N

物化性质

• 熔点：
  240-241 °C
• 沸点：
  340.4±25.0 °C(Predicted)
• 密度：
  1.309±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P264,P270,P301+P312,P330,P501
• 危险性描述：
  H302

反应信息

• 作为反应物：
  描述：

  2,3-二甲基丁-2-烯二酸 在 三氯化铝 、 五氯化磷 作用下， 生成 2,3-二甲基马来酸酐
  参考文献：
  名称：

  Studies on Unsaturated 1,4-Dicarbonyl Compounds. VIII. Some New Derivatives of Dimethylfumaric Acid

  摘要：

  DOI：

  10.1021/ja01331a044
• 作为产物：
  描述：

  2,3-二甲基马来酸酐 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 50.0h， 以26%的产率得到2,3-二甲基丁-2-烯二酸
  参考文献：
  名称：

  （Z）-和（E）-2,3-二甲基（1,1,1,4,4,4- 2 H 6）丁-2-烯的同调异构体：立体特异性环氧化的机理探针

  摘要：

  通过明确的方法，合成了（Z）-和（E）-2，3-二甲基（1，1，1，4，4，4- 2 H 6）-2-烯（3）并转化为环氧化物4含3-氯过苯甲酸。同位素异构体烯烃和环氧化物分别通过1 H-NMR在400 MHz下检测。（Z）-3与[Rh I Cl（PPh 3）3 ] /异丙苯氢过氧化物的环氧化反应产生（Z）-和（E）-4的1：1混合物，而（Z）-3与[ Z ] -3的[铁III（tpp）] Cl / PhIO仅得到（Z）-4（tpp ＝四苯基卟啉）。

  DOI：

  10.1002/hlca.19920750310

文献信息

• [EN] FUMARATE ANALOGS AND USES THEREOF IN THE TREATMENT OF AN AUTOIMMUNE DISEASE OR AN INFLAMMATORY DISEASE<br/>[FR] ANALOGUES DE FUMARATE ET LEURS UTILISATIONS DANS LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE OU D'UNE MALADIE INFLAMMATOIRE
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2016022434A1

  公开（公告）日：2016-02-11

  Aspects of the present disclosure include compounds of formula (A) that find use for the treatment of a variety of autoimmune and inflammatory diseases and disorders. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes. Formula (A).

  本公开涉及的方案包括式（A）的化合物，该化合物可用于治疗各种自身免疫性和炎症性疾病和疾病。本公开的实施例还涉及包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。方案（A）。
• [EN] (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES<br/>[FR] (AZA)INDOLE, BENZOTHIOPHÈNE ET BENZOFURAN-3-SULFONAMIDES
  申请人：UCB PHARMA GMBH

  公开号：WO2018122232A1

  公开（公告）日：2018-07-05

  Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

  揭示了具有GPR17调节特性的磺胺类化合物，可用于治疗或预防各种中枢神经系统和其他疾病，特别是用于预防和治疗髓鞘疾病或紊乱。
• SUBSTITUTED OR UNSUBSTITUTED ALLYL GROUP-CONTAINING MALEIMIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND COMPOSITION AND CURED PRODUCT USING SAID COMPOUND
  申请人：DIC CORPORATION

  公开号：US20200325101A1

  公开（公告）日：2020-10-15

  Bismaleimides (BMI) exhibit excellent heat resistance (high Tg and high resistance to thermal decomposition) compared to epoxy resins and phenolic resins, and therefore, in recent years, more attention is paid to bismaleimides as a resin material for the next-generation devices represented by SiC power semiconductors, in addition to the investigation on the use of bismaleimides for electronic material applications. As such, conventional BMI's are known as highly heat-resistant resins; however, there is a demand for a resin having higher heat resistance for advanced material applications and the like. Thus, an object of the invention is to provide a novel maleimide compound having superior heat resistance. Disclosed is a substituted or unsubstituted allyl group-containing maleimide compound having a structure with three or more benzene rings, having one or more groups each having a substituted or unsubstituted allyl group, and having one or more maleimide groups.

  亚苯基马来酰亚胺化合物，具有三个或更多苯环的结构，含有一个或多个取代或未取代的烯丙基团，以及一个或多个马来酰亚胺基团，具有卓越的耐热性。
• SUBSTITUTED PYRAZOLOPYRIMIDINES AS IRAK4 INHIBITORS
  申请人：Bayer AG

  公开号：EP3800188A1

  公开（公告）日：2021-04-07

  The present application relates to novel pyrazolopyrimidine derivatives for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases in humans and in animals, especially of proliferative disorders, autoimmune disorders, metabolic and inflammatory disorders characterized by an overreacting immune system, in particular rheumatological disorders, inflammatory skin disorders, cardiovascular disorders, lung disorders, eye disorders, neurological disorders, pain disorders and cancer, in human as well as of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

  本申请涉及用于治疗和/或预防疾病的新的吡唑并嘧啶衍生物，以及将它们用于生产用于治疗和/或预防人类和动物疾病的药物，尤其是增殖性疾病、自身免疫性疾病、代谢和炎症性疾病，这些疾病的特点是免疫系统过度反应，特别是风湿性疾病、炎症性皮肤病、心血管疾病、肺部疾病、眼病、神经系统疾病、疼痛疾病和癌症，在人类中，以及动物的过敏性/或炎症性疾病，特别是异位性皮炎和/或跳蚤过敏性皮炎，尤其是在家养动物中，特别是在狗中。
• COMPOUNDS AND THEIR USES AS MIF INHIBITORS
  申请人：Nanjing Immunophage BioTech Co., Ltd.

  公开号：US20210403484A1

  公开（公告）日：2021-12-30

  The present invention provides compounds of Formula I which can be used as macrophage migration inhibitory factor (MIF) inhibitors; methods for the production of the compounds of the invention; pharmaceutical compositions comprising the compounds of the invention; as well as uses and methods for treating a disease mediated by MIF by administering the compounds of the invention.

  本发明提供了一种可以用作巨噬细胞迁移抑制因子（MIF）抑制剂的化合物I的公式；本发明化合物的制备方法；包括本发明化合物的药物组合物；以及通过给予本发明化合物来治疗由MIF介导的疾病的用途和方法。